607TiPBIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703). (23rd October 2018) - Kotani, D; Bando, H; Masuishi, T; Komatsu, Y; Yamaguchi, K; Nakajima, T E; Satoh, T; Nishina, T; Esaki, T; Nomura, S; Sakamoto, S; Iida, S; et al.